Patient coalition appeals Czech CBD restriction plan

Patient groups in Europe and beyond are urging the Czech Government and EU institutions to publish evidence before moving to restrict CBD. The appeal, launched in Prague on 17 June 2026, argues that any response should target dangerous synthetic cannabinoids and protect patients’ rights instead of quietly limiting legal CBD access. Why it matters: - Patient organisations say a CBD restriction could push tested, legal products out of regulated channels and into a harder-to-police grey market. - The coalition argues that patients could lose access to a substance already used in an EU-authorised medicine for severe epilepsy. - The groups want policymakers to focus enforcement on dangerous synthetic and semi-synthetic cannabinoids, not on patient-access products. What happened: - A coalition of patient organisations from Europe and beyond launched an appeal and public petition, “Care Before Discrimination is a Human Right,” in Prague on 17 June 2026. - The appeal challenges Czech plans to treat CBD as a “drug precursor” and asks authorities to publish the evidence before acting. - The petition is live at cbdhumanright.org/sign , and the appeal is being released in six languages. - The launch came hours before the Czech Government’s Council for Addiction Policy met on the afternoon of 17 June. The details: - Czech authorities are considering precursor-based measures on CBD, including placing it on a European precursor list and restricting how it can be processed under Czech law. - The coalition says CBD is not scheduled under international drug-control conventions. - The coalition also points to a purified CBD medicine already authorised in the EU for severe forms of epilepsy. - The International Narcotics Control Board has said the evidence that CBD is used to make illicit semi-synthetic cannabinoids is “limited.” - The coalition says genuinely dangerous products sold through grey-market channels need direct enforcement, age limits and quality rules. - The appeal calls for quality standards, contaminant testing, honest labelling, age limits and enforcement against dangerous synthetic products. - The coalition says it is not opposing regulation and is objecting to a quiet administrative shortcut based on unpublished evidence. - Pavel Kubů of KOPAC said patients are asking not to be pushed into the shadows and want the government to show the evidence, hear affected patients and explain why existing rules are insufficient. - The coalition’s formal title for the appeal is “Care Before Discrimination — Patients’ Rights and the Proposed Restriction of CBD.” - The coalition includes Aube, Centrum Paraple, Dosemociones, Fuck Cancer, KOPAC, Mothers for Cannabis, PatientsCann and Verein Medcan, with more groups joining. - The coalition says it does not promote, sell or link to any CBD product. - The full appeal and press resources are available at the coalition’s website . Between the lines: - The appeal is as much about process as policy, with the coalition framing the issue as one of transparency, patient consultation and proportional regulation. - The group is trying to separate legal CBD from illicit cannabinoid products, arguing that public health protection depends on targeted enforcement rather than broad restriction. - By releasing the appeal in multiple languages and before a Czech policy meeting, the coalition is signaling a wider European campaign, not just a national dispute. What’s next: - The coalition wants the Czech Government, EU institutions and UN drug-control bodies to publish evidence before any CBD restriction is introduced. - The appeal also asks policymakers to avoid covert or purely administrative measures and to consult patient organisations before decisions are made. - The petition remains open for signatures at cbdhumanright.org/sign .